Personal tools
You are here: Home Recent News FDA Advisory Panel Votes for Approval of New Diabetes Drug

FDA Advisory Panel Votes for Approval of New Diabetes Drug

10 of 15 members of a Food and Drug Administration panel voted to recommend approval of diabetes drug canagliflozin, despite cardiovascular concerns.

"A US Food and Drug Administration advisory panel voted 10 to 5 in favor of approving the novel glucose-lowering agent canagliflozin (Invokana, Janssen Research & Development) for the treatment of adults with type 2 diabetes. But the FDA's Endocrinologic and Metabolic Drugs Advisory Committee also voted 8 to 7 that they had concerns about the cardiovascular safety of the agent."

Read more.

Document Actions